MA51433A - Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase - Google Patents

Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase

Info

Publication number
MA51433A
MA51433A MA051433A MA51433A MA51433A MA 51433 A MA51433 A MA 51433A MA 051433 A MA051433 A MA 051433A MA 51433 A MA51433 A MA 51433A MA 51433 A MA51433 A MA 51433A
Authority
MA
Morocco
Prior art keywords
kinase inhibitor
piperidine derivative
aminomethyl piperidine
aminomethyl
derivative
Prior art date
Application number
MA051433A
Other languages
English (en)
Inventor
Seung Hwarn Jeong
Bo-Kyoung Kim
In Woo Kim
Nam Youn Kim
Jun Hee Lee
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of MA51433A publication Critical patent/MA51433A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
MA051433A 2017-12-28 2018-12-28 Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase MA51433A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170183062A KR102577242B1 (ko) 2017-12-28 2017-12-28 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체

Publications (1)

Publication Number Publication Date
MA51433A true MA51433A (fr) 2021-04-07

Family

ID=67067897

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051433A MA51433A (fr) 2017-12-28 2018-12-28 Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase

Country Status (23)

Country Link
US (1) US11407754B2 (fr)
EP (1) EP3733674B1 (fr)
JP (1) JP7024091B2 (fr)
KR (1) KR102577242B1 (fr)
CN (1) CN111527088B (fr)
AU (1) AU2018394996B2 (fr)
BR (1) BR112020013237A2 (fr)
CA (1) CA3085160C (fr)
CL (1) CL2020001749A1 (fr)
CO (1) CO2020007156A2 (fr)
DO (1) DOP2020000111A (fr)
EC (1) ECSP20035588A (fr)
ES (1) ES2924225T3 (fr)
MA (1) MA51433A (fr)
MX (1) MX2020006798A (fr)
MY (1) MY196572A (fr)
PE (1) PE20210549A1 (fr)
PH (1) PH12020550993A1 (fr)
RU (1) RU2756505C1 (fr)
SA (1) SA520412334B1 (fr)
SG (1) SG11202004916YA (fr)
TN (1) TN2020000081A1 (fr)
WO (1) WO2019132561A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392368B2 (en) 2017-08-01 2019-08-27 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
CA3084962C (fr) 2017-12-28 2022-08-09 Daewoong Pharmaceutical Co., Ltd. Derives d'oxy-fluoropiperidine utilises en tant qu'inhibiteur de kinase
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CA3125039A1 (fr) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine,1,2,4-triazolo[4,3-a]pyridine et imidazo[1,5-a]pyrazine utilisees en tant qu'inhibiteurs de jak
KR102228668B1 (ko) * 2019-10-08 2021-03-17 (주)부흥산업사 메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법
CN112824381B (zh) * 2019-11-21 2024-04-26 广东东阳光药业股份有限公司 一种哌啶胺的制备方法
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
CN115023428B (zh) * 2020-01-21 2025-04-08 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2021147953A1 (fr) * 2020-01-21 2021-07-29 江苏先声药业有限公司 Dérivé cyclique pyrimidino à cinq chaînons et application correspondante
CN113214265B (zh) * 2020-01-21 2023-07-07 江苏先声药业有限公司 嘧啶并五元环类化合物
TW202214643A (zh) * 2020-09-22 2022-04-16 大陸商江蘇先聲藥業有限公司 嘧啶并吡咯類化合物
CN114315838B (zh) * 2020-09-30 2024-09-03 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (fr) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 Composé hétérocyclique contenant de l'azote et son utilisation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
CN105362277A (zh) 2008-07-16 2016-03-02 药品循环有限公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
MD20140023A2 (ro) 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
DK2880035T3 (en) 2012-08-06 2017-03-06 Acea Biosciences Inc Hitherto UNKNOWN PYRROLOPYRIMIDINE COMPOUNDS AS PROTEIN CHINAS INHIBITORS
TR201904813T4 (tr) 2012-11-08 2019-04-22 Compac Tech Limited Bir derecelendirme aparatı için ürün taşıyıcısı.
US9346812B2 (en) 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
US9840517B2 (en) * 2013-09-18 2017-12-12 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
WO2015083028A1 (fr) 2013-12-05 2015-06-11 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
CN105732637B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN108934162A (zh) 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
CN113135920A (zh) 2016-06-30 2021-07-20 株式会社大熊制药 吡唑并嘧啶衍生物作为激酶抑制剂
CN106432294B (zh) 2016-09-19 2018-01-30 淮北师范大学 发光配合物及其制备方法
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CA3084962C (fr) 2017-12-28 2022-08-09 Daewoong Pharmaceutical Co., Ltd. Derives d'oxy-fluoropiperidine utilises en tant qu'inhibiteur de kinase

Also Published As

Publication number Publication date
ECSP20035588A (es) 2020-07-31
ES2924225T3 (es) 2022-10-05
RU2756505C1 (ru) 2021-10-01
SG11202004916YA (en) 2020-06-29
EP3733674B1 (fr) 2022-06-29
KR102577242B1 (ko) 2023-09-11
BR112020013237A2 (pt) 2020-12-01
AU2018394996B2 (en) 2021-08-05
MY196572A (en) 2023-04-19
NZ765152A (en) 2024-02-23
KR20190080541A (ko) 2019-07-08
PH12020550993A1 (en) 2021-04-19
US20210188854A1 (en) 2021-06-24
JP7024091B2 (ja) 2022-02-22
CN111527088B (zh) 2022-12-30
DOP2020000111A (es) 2020-09-30
EP3733674A1 (fr) 2020-11-04
JP2021507923A (ja) 2021-02-25
MX2020006798A (es) 2020-09-03
CL2020001749A1 (es) 2020-11-06
US11407754B2 (en) 2022-08-09
AU2018394996A2 (en) 2020-07-16
AU2018394996A1 (en) 2020-06-25
CA3085160C (fr) 2021-12-07
TN2020000081A1 (en) 2022-01-06
CA3085160A1 (fr) 2019-07-04
PE20210549A1 (es) 2021-03-17
EP3733674A4 (fr) 2021-06-09
SA520412334B1 (ar) 2022-11-03
WO2019132561A1 (fr) 2019-07-04
CN111527088A (zh) 2020-08-11
CO2020007156A2 (es) 2020-06-19
WO2019132561A8 (fr) 2020-06-11

Similar Documents

Publication Publication Date Title
MA51433A (fr) Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase
EP3656769A4 (fr) Composé aryl-phosphore-oxygène utilisé en tant qu'inhibiteur de kinase egfr
EP3733673A4 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
IL257520A (en) Drone box
EP3533787A4 (fr) Composé de pyridone en tant qu'inhibiteur de c-met
EP3697787A4 (fr) Composé hétérocyclique à utiliser en tant qu'inhibiteur de protéine kinase
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
DK3612524T3 (da) 6-pyrimidin-isoindol-derivat som erk1/2-inhibitor
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA53643A (fr) Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6
LT3202766T (lt) Izoksazolo darinys, kaip mutuotos izocitrato dehidrogenazės 1 inhibitorius
EP3102571A4 (fr) Pyrimidines substituées utiles en tant qu'inhibiteurs de kinase d'egfr-t790m
EP3532479A4 (fr) Composés amides en tant qu'inhibiteurs de kinase
IL269695A (en) Compounds useful as inhibitors of alcat 1
EP3421454A4 (fr) Dérivé de pipéridine
DK3405287T3 (da) Slidbeskyttelseselement til en fragmenteringsmaskine
EP3317427A4 (fr) Biomarqueurs de réponse à des inhibiteurs sélectifs d'aurora a kinase
EP3444345A4 (fr) Dérivé d'arnmicro-143
MA51284A (fr) Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho